Targeting BCL-2 regulated apoptosis in cancer

Open Biol. 2018 May;8(5):180002. doi: 10.1098/rsob.180002.

Kirsteen J Campbell ¹ ², Stephen W G Tait ³ ²

Affiliations

1 Cancer Research UK Beatson Institute, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK [email protected].
2 Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.
3 Cancer Research UK Beatson Institute, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK [email protected].

PMID: 29769323 DOI: 10.1098/rsob.180002

Abstract

The ability of a cell to undergo mitochondrial Apoptosis is governed by pro- and anti-apoptotic members of the Bcl-2 protein family. The equilibrium of pro- versus anti-apoptotic Bcl-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health. When unbalanced, the Bcl-2 Family can act as a barrier to Apoptosis and facilitate tumour development and resistance to Cancer therapy. Here we discuss the Bcl-2 Family, their deregulation in Cancer and recent pharmaceutical developments to target specific members of this family as Cancer therapy.

Keywords

BAX/BAK; BCL-2 family; apoptosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.